PPT-A ten-year evolution of a multidrug-resistant tuberculosis (MDR-TB) outbreak in an HIV-negative

Naira Dekhil 1 Besma Mhenni 1 Raja Haltiti 2 and Helmi Mardassi 1 speaker   1 Unit of Typing amp Genetics of Mycobacteria Institut Pasteur de Tunis Tunisia. The TB situation in 2013. :. Findings from the joint TB surveillance and monitoring report by . ECDC . and . the WHO Regional Office for Europe . ECDC TB Team. European Centre for Disease Prevention and Control. P. Stogsdill, MD, FIDSA. Sept 2013. Bad bugs, No drugs. NO ESKAPE. E. nterococcus . faecium. S. taphylococcus . aureus. K. lebsiella. . pneumoniae. . C. lostridium. . difficile. A. cinetobacter. LT . Christina Jamros, DO (Associate. ) . CDR . Ryan Maves, MD (Fellow. ) . CAPT . Mary . Bavaro. , MD (Fellow). Department of Internal . Medicine. Naval . Medical Center, San Diego, CA. Disclosure. I have no relevant financial relationships with any commercial supporters.. update 2011. Between 2011 and 2015 …. Increase in TB cases tested for R & H yearly from 0.8 million to 1.9 million. 1 . million . multidrug-resistant TB (. MDR-TB) . patients detected and put on treatment. Akujobi. CN, . Okoro. CE, . Anyabolu. AE, . Okonkwo. RC, . Onwunzo. MC and . Chukwuka. CP. Tuberculosis (TB) is the most common opportunistic infection in Human . Immuno. d. eficiency . Virus (HIV. ries 14 61 contributed data on 17690 isolates whichThese drugs are more costly toxic and less effective thanfirst-line drugs used for routine treatment of TB with other diseases resistance to TB drugs meningitis in the United States, 1993-2005. Presenter: . Christopher Vinnard. World Epidemiology Congress 2011. Edinburgh, Scotland. Disclosures. No authors have financial or non-financial conflicts of interests that may be relevant to this presentation. Carbapenems. . Customize this presentation with your organization’s logo, etc.. 1. 3/17/2014. Presentation Objectives. Brief overview on microbiology and antibiotics. Describe antibiotic resistant organisms with a focus on . — 91 — and extensively drug resistant TB — 92 — and extensively drug resistant TBficient anti TB programs were the most affected by multi-resistance. Global resistance figures prov Pérez-Lago L, Lirola M, Navarro Y, Herranz M, Ruiz-Serrano M, Bouza E, et al. Co-infection with Drug-Susceptible and Reactivated Latent Multidrug-Resistant Mycobacterium tuberculosis. Emerg Infect Dis. 2015;21(11):2098-2100. https://doi.org/10.3201/eid2111.150683. Last Updated: December 28, 2022. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Subcutaneous . Lenacapavir. Administer as Subcutaneous Injection. Take with or without food. Oral . Lenacapavir. Lenacapavir. Dierberg KL, Dorjee K, Salvo F, Cronin WA, Boddy J, Cirillo D, et al. Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India. Emerg Infect Dis. 2016;22(3):463-468. https://doi.org/10.3201/eid2203.140732. CAPELLA. Lenacapavir. in Multidrug Resistant HIV. CAPELLA Study: Background. Source: Segal-Maurer S, et al. N . Engl. J Med. 2022;386:1793-1803. . Background. Phase 3, randomized, trial with oral and subcutaneous . John Stelling, MD, MPH, . jstelling@whonet.org. Brigham and Women’s Hospital, Harvard Medical School, Boston. WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. Webinar agenda. Comments on the WHONET Webinar series.